Cellular energy: nootropics and compounds | sci-wiki

Idebenone

Idebenone is a synthetic analog of coenzyme Q10 (ubiquinone), a short-chain benzoquinone with antioxidant and mitochondrial properties. Originally developed by Takeda for Alzheimer's disease and other cognitive disorders, it is now used mainly as an approved treatment for Leber's hereditary optic neuropathy, a rare inherited cause of vision loss. It has also been studied in other mitochondrial and neuromuscular diseases and is used as an antioxidant ingredient in some skincare products.

1 outlet

Nootropic

CX-546

CX-546 is a benzoxazine ampakine developed by Cortex Pharmaceuticals as a positive allosteric modulator of AMPA-type glutamate receptors. It is a first-generation, high-impact ampakine that markedly slows receptor deactivation and desensitization, boosting excitatory transmission, long-term potentiation, and neurotrophin expression in the hippocampus. Widely used as a laboratory tool compound, it has illuminated how AMPA modulation drives synaptic plasticity, astrocyte energetics, and BDNF signaling. It never became a clinical product but remains an important reference ampakine.

reference

Mitochondrial

Decylubiquinone

Decylubiquinone is a short-chain synthetic analog of coenzyme Q10 in which the long polyisoprenoid tail is replaced by a simple ten-carbon decyl chain, yielding a redox-active ubiquinone with greater aqueous handling and cell permeability. It participates in mitochondrial electron transport as a ubiquinone surrogate and can enhance respiratory complex activity, while also acting as a reactive-oxygen-species scavenger that blocks the redox-triggered mitochondrial permeability transition. Widely employed as a laboratory ubiquinone standard, it has been proposed as a candidate antioxidant along the same lines as idebenone. It is chiefly a research compound rather than a marketed supplement.

reference

Mitochondrial

Dexpramipexole

Dexpramipexole (KNS-760704) is the R-enantiomer of the dopamine agonist pramipexole, stripped of most dopaminergic activity and repurposed as a mitochondrial bioenergetic agent. It binds the F1Fo ATP synthase and increases mitochondrial ATP production, and it is brain-penetrant, orally active, and generally well tolerated. Despite a promising phase 2 signal in amyotrophic lateral sclerosis, it failed to beat placebo in the large phase 3 EMPOWER trial, though preclinical work continued to show bioenergetic protection in stroke models. Its enantiomeric relationship to a marketed Parkinson drug and its ATP-synthase mechanism make it a distinctive entry in the mitochondrial nootropic and neuroprotection landscape.

reference

Mitochondrial

Mitochonic Acid 5

Mitochonic Acid 5 (MA-5) is a synthetic indole-3-acetic acid derivative that boosts cellular ATP production through a mechanism independent of the classical electron transport chain. Rather than shuttling electrons, it binds the inner-membrane crista-junction protein mitofilin and promotes oligomerization of ATP synthase and formation of respiratory supercomplexes, improving the efficiency of energy generation while lowering reactive oxygen species. It rescued survival of fibroblasts from patients with diverse mitochondrial diseases and improved renal, cardiac, and muscle outcomes in animal and cell models. It is an investigational mitochondrial homing compound of unusual mechanistic interest.

reference

Mitochondrial

MitoTEMPO

MitoTEMPO is a mitochondria-targeted superoxide dismutase mimetic created by conjugating the nitroxide antioxidant TEMPO to a lipophilic triphenylphosphonium cation. The positively charged phosphonium moiety drives the molecule to accumulate several-hundred-fold inside the negatively charged mitochondrial matrix, where the nitroxide catalytically scavenges superoxide and alkyl radicals at their principal source. It is one of the most widely used experimental tools for testing whether mitochondrial reactive oxygen species drive a given disease process, and it has shown therapeutic effects in preclinical models of hypertension, ferroptosis, and inflammation. It is a research reagent rather than a clinical drug.

reference

Mitochondrial

Olesoxime

Olesoxime (TRO19622) is an orally active, brain-penetrant cholesterol-oxime developed as a mitochondrial-targeted neuroprotectant. It concentrates at the outer mitochondrial membrane, binds the translocator protein TSPO and the voltage-dependent anion channel VDAC, and prevents opening of the mitochondrial permeability transition pore under oxidative and calcium stress. Originally identified for its ability to keep motor neurons alive when deprived of neurotrophic factors, it was advanced through clinical trials in amyotrophic lateral sclerosis and spinal muscular atrophy. Although pivotal endpoints were not met, its favorable safety and clean mechanism keep it a reference compound for permeability-transition-pore-targeted neuroprotection.

reference

Mitochondrial

Omaveloxolone

Omaveloxolone (RTA-408, brand name Skyclarys) is an orally active synthetic oleanane triterpenoid that pharmacologically activates the master antioxidant transcription factor Nrf2 while suppressing NF-kappaB-driven inflammation. By restoring Nrf2 signaling, which is chronically suppressed in Friedreich ataxia, it targets the intertwined oxidative, inflammatory, and bioenergetic deficits that impair mitochondrial ATP production. It became the first therapy approved for Friedreich ataxia in the United States after the MOXIe trial demonstrated meaningful improvement in neurological function. It represents the mitochondrial-longevity strategy of upregulating endogenous antioxidant defenses rather than supplying an exogenous antioxidant.

reference

Mitochondrial

Sonlicromanol

Sonlicromanol (KH176) is an orally active, blood-brain-barrier-penetrant small molecule derived from the vitamin E analog Trolox, developed specifically for inherited mitochondrial disease. It acts as a dual redox modulator, directly scavenging reactive oxygen species and reactivating the peroxiredoxin-thioredoxin antioxidant system, and its active metabolite KH176m additionally suppresses inflammatory prostaglandin production. The compound has advanced through phase 2 clinical trials in adults and children with genetically confirmed mitochondrial disease, including the m.3243A>G mutation that causes MELAS. It is one of the most clinically mature purpose-built mitochondrial protectants of its generation.

reference

Mitochondrial

Vatiquinone

Vatiquinone (EPI-743) is an orally bioavailable para-benzoquinone derived from alpha-tocotrienol, developed as a mitochondrial-protective agent for inherited mitochondrial disease and other disorders driven by oxidative stress. It is structurally related to coenzyme Q10 and idebenone but acts principally by suppressing ferroptotic lipid peroxidation rather than by shuttling electrons in the respiratory chain. The compound inhibits 15-lipoxygenase and restores the reduced glutathione pool, protecting neurons from iron- and lipid-dependent death. It has been evaluated in numerous clinical trials in mitochondrial epilepsy, Friedreich ataxia, and Leigh syndrome, with mixed but occasionally encouraging results on seizure burden.

reference